Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission

May 23rd 2017

Daniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.

FDA Grants Priority Review to Copanlisib for Follicular Lymphoma

May 17th 2017

The FDA has granted a priority review designation to copanlisib as a treatment for patients with relapsed/refractory follicular lymphoma who have received at 2 least prior therapies, according to Bayer, the manufacturer of the PI3K dual-isoform inhibitor.

Subcutaneous Rituximab Results Published as FDA Decision Nears

May 15th 2017

Results from the phase III SABRINA trial showed that subcutaneous administration of rituximab produced nearly identical response rates and toxicity as IV administration in the first-line treatment of follicular lymphoma.

Kite Reports Cerebral Edema Death in ZUMA-1 CAR T-Cell Trial

May 9th 2017

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

Neelapu Hopeful FDA Will Approve Axicabtagene Ciloleucel for NHL

May 8th 2017

Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.

Immunotherapy Demonstrates Early Promise Across Lymphoma Subgroups

April 27th 2017

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

Complete Response to Chemo Critical in CLL Patients Who Develop Hodgkin Lymphoma

April 24th 2017

Achieving a complete response following ABVD chemotherapy offered the best chance for survival for patients with chronic lymphocytic leukemia who developed Hodgkin lymphoma following Richter transformation, according to a retrospective study published in the American Journal of Hematology.

FDA Grants CTL019 Breakthrough Designation for DLBCL

April 18th 2017

The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

Expert Discusses State of Follicular Lymphoma Treatment in 2017

April 13th 2017

Nathan Fowler, MD, discusses the current management of high-risk follicular lymphoma and ongoing developments in the field.

Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL

April 12th 2017

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Dr. Salles on New Agents Being Investigated in Follicular Lymphoma

April 11th 2017

Gilles Salles MD, PhD, Centre Hospitalier Lyon-Sud, discusses new agents being investigated for patients with follicular lymphoma.

PI3K Inhibitor Copanlisib Active in Relapsed/Refractory Lymphoma

April 5th 2017

According to results from the phase II CHRONOS-1 trial, a majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib.

CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response

April 4th 2017

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

CAR T-Cell Response Rate Tops 80% in NHL Trial

April 4th 2017

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Dr. Neelapu on Primary Results of the ZUMA-1 Trial in NHL

April 2nd 2017

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

FDA Submission Completed for Axicabtagene Ciloleucel in NHL

April 1st 2017

A biologics license application has been submitted for axicabtagene ciloleucel as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell Lymphoma

March 30th 2017

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

Dr. Dogan on Updated WHO Classifications in DLBCL

March 30th 2017

Ahmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Fowler on Different Responses to Therapy for Follicular Lymphoma

March 30th 2017

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.

New Standards Are Emerging for Follicular Lymphoma and CLL

March 20th 2017

Controlling indolent non-Hodgkin lymphoma remains a priority as it has the potential to transform to aggressive or high-grade lymphoma.